Tlalnepantla, Mexico
Tlalnepantla, Mexico

Mexichem produces and sells of chemicals products worldwide. It was founded in 1998 and located in Tlalnepantla, Mexico. Wikipedia.


Time filter

Source Type

Patent
Mexichem | Date: 2016-08-29

A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).


Patent
Mexichem | Date: 2016-12-08

A new chromium-containing fluorination catalyst is described. The catalyst comprises an amount of zinc that promotes activity. The zinc is contained in aggregates which have a size across their largest dimension of up to 1 micron. The aggregates are distributed throughout at least the surface region of the catalyst and greater than 40 weight % of the aggregates contain a concentration of zinc that is within 1 weight % of the modal concentration of zinc in those aggregates.


Patent
Mexichem | Date: 2017-04-26

The invention relates to a process for removing one or more undesired (hydro)halocarbon compounds containing a =CF_(2) moiety from a (hydro)fluoroalkene that does not contain a =CF_(2) moiety, the process comprising contacting a composition comprising the (hydro)fluoroalkene and one or more undesired (hydro)halocarbon compounds with an aluminium-containing absorbent, activated carbon, or a mixture thereof, wherein the or each undesired (hydro)halocarbon compound is present in an amount of from about 0.1 to about 1000 ppm, based on the weight of the composition comprising the (hydro)fluoroalkene and one or more undesired (hydro)halocarbon compounds.


Patent
Mexichem | Date: 2017-01-17

A process for removing one or more undesired (hydro)halocarbon compounds containing a CF_(2 )moiety from a (hydro)fluoroalkene that does not contain a CF_(2 )moiety, the process comprising contacting a composition comprising the (hydro)fluoroalkene and one or more undesired (hydro)halocarbon compounds with an aluminum-containing absorbent, activated carbon, or a mixture thereof, wherein the or each undesired (hydro)halocarbon compound is present in an amount of from about 0.1 to about 1000 ppm, based on the weight of the composition comprising the R-1234yf and one or more undesired (hydro)halocarbon compounds.


A process for preparing 2,3,3,3-tetrafluoropropene (CF_(3)CFCH_(2)). 3,3,3-trifluoro-2-chloropropene (CF_(3)CClCH_(2)) is fluorinated with HF in the vapour phase in the presence of a chromia-containing catalyst to produce an intermediate composition 1,1,1,2,2-pentafluoropropane (CF_(3)CF_(2)CH_(3)), which is dehydrofluorinated to produce CF_(3)CFCH_(2).


Patent
Mexichem | Date: 2016-11-21

A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).


A process for treating a composition comprising one or more desired (hydro)fluoroolefins and one or more undesired halogenated ethanes, halogenated methanes or mixtures thereof so as to reduce the concentration of at least one undesired halogenated ethane or halogenated methane, the process comprising contacting the composition with an adsorbent comprising pores having openings which have a size across their largest dimension of about 6 A or less.


1. The invention provides a process for the preparation of 2,3,3,3-tetrafluoropropene (1234yf), the process comprising:(a) contacting 1,1,2,3,3,3-hexafluoropropene (1216) with hydrogen in the presence of a hydrogenation catalyst to produce 1,1,2,3,3,3-hexafluoropropane (236ea);(b) dehydrofluorinating 236ea to produce 1,2,3,3,3-pentafluoropropene (1225ye);(c) contacting 1225ye with hydrogen in the presence of a hydrogenation catalyst to produce 1,2,3,3,3-pentafluoropropane (245eb); and(d) dehydrofluorinating 245eb to produce 1234yf;wherein the process is carried out in a semi-batch manner using one hydrogenation reactor and one dehydrofluorination reactor, wherein steps (a), (b), (c) and (d) are conducted sequentially in that order.


Patent
Mexichem | Date: 2016-01-04

The invention relates to a process for removing one or more undesired (hydro)halocarbon compounds from a (hydro)fluoroalkene, the process comprising contacting a composition comprising the (hydro)fluoroalkene and one or more undesired (hydro)halocarbon compounds with an aluminium-containing absorbent, activated carbon, or a mixture thereof.


Patent
Mexichem | Date: 2016-09-20

A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Loading Mexichem collaborators
Loading Mexichem collaborators